Q1 EPS Estimates for Kodiak Sciences Decreased by Analyst

Key Points

• HC Wainwright cut Q1 2026 EPS to ($0.94) from ($0.75) and trimmed FY2026–FY2030 forecasts, but maintained a Buy rating and a $58 price target.
• Kodiak reported Q4 EPS of ($1.04), missing consensus by $0.02, and the stock fell about 5.1% after the results while trading near $40.63 (market cap ≈ $2.51B).
• Institutional ownership is very high (~89.06%), with large investors like Baker Bros., Vanguard and State Street increasing stakes, indicating strong institutional support despite analyst cuts.

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - HC Wainwright cut their Q1 2026 EPS estimates for Kodiak Sciences in a research report issued on Wednesday, April 1st. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($0.94) per share for the quarter, down from their previous estimate of ($0.75). HC Wainwright has a "Buy" rating and a $58.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' Q2 2026 earnings at ($0.96) EPS, Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.85) EPS, FY2026 earnings at ($3.56) EPS, FY2027 earnings at ($3.19) EPS, FY2028 earnings at ($1.94) EPS, FY2029 earnings at $0.19 EPS and FY2030 earnings at $3.05 EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last announced its quarterly earnings data on Tuesday, March 31st. The company reported ($1.04) EPS for the quarter, missing the consensus estimate of ($1.02) by ($0.02).

A number of other research firms have also recently commented on KOD. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Kodiak Sciences in a report on Thursday, January 22nd. UBS Group increased their price objective on Kodiak Sciences from $50.00 to $80.00 and gave the company a "buy" rating in a report on Friday, March 27th. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Kodiak Sciences has an average rating of "Moderate Buy" and an average price target of $35.43.

Kodiak Sciences Stock Down 5.1%

Kodiak Sciences stock opened at $40.63 on Friday. Kodiak Sciences has a twelve month low of $1.92 and a twelve month high of $45.60. The firm has a 50 day moving average price of $26.08 and a 200-day moving average price of $22.62. The company has a market capitalization of $2.51 billion, a P/E ratio of -9.41 and a beta of 2.39.

Hedge Funds Weigh In On Kodiak Sciences

Several large investors have recently modified their holdings of the business. Baker BROS. Advisors LP raised its position in shares of Kodiak Sciences by 15.1% in the fourth quarter. Baker BROS. Advisors LP now owns 19,919,186 shares of the company's stock valued at $556,940,000 after purchasing an additional 2,608,696 shares during the period. Vanguard Group Inc. boosted its holdings in Kodiak Sciences by 18.6% in the 4th quarter. Vanguard Group Inc. now owns 2,313,395 shares of the company's stock worth $64,683,000 after buying an additional 363,103 shares during the period. Braidwell LP bought a new position in Kodiak Sciences in the 4th quarter worth approximately $57,955,000. Adage Capital Partners GP L.L.C. grew its stake in Kodiak Sciences by 55.1% in the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 2,055,707 shares of the company's stock valued at $7,668,000 after buying an additional 730,000 shares in the last quarter. Finally, State Street Corp grew its stake in Kodiak Sciences by 108.1% in the 4th quarter. State Street Corp now owns 1,732,015 shares of the company's stock valued at $48,427,000 after buying an additional 899,572 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: Company reported advancing pipeline and strong Phase III data for Zenkuda that management highlighted alongside Q4/2025 results — this progress and accelerated regulatory planning support upside expectations for KOD. Kodiak Announces Q4 and FY2025 Results
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $58 price target even as it trimmed forecasts — that continued analyst endorsement can provide investor support and a clear upside reference point.
• Neutral Sentiment: Q4 results showed a wider-than-expected loss, but commentary focused investor attention on pipeline milestones rather than only near-term P&L metrics. Zacks: Q4 Loss Wider Than Expected
• Negative Sentiment: Multiple analysts (Lifesci Capital and HC Wainwright) cut near-term EPS estimates across Q1–Q4 2026 and lowered FY2026–FY2029/2030 forecasts — these downward revisions increase short-term earnings uncertainty and can pressure the stock. (Market commentary and analyst notes issued April 1)
• Negative Sentiment: Some cuts are large and extend into multi-year forecasts (HC Wainwright cut FY2026–FY2029/2030 estimates; Lifesci trimmed FY2026), signaling analysts see a longer recovery path to profitability — this raises risk for investors focused on near-term fundamentals.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company's proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak's research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak's pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.